UB Paderborn / Katalog / Suche / in CDI

Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic Controls

Clinical cancer research, 2022-09, Vol.28 (18), p.3908-3910

2022

Volltextzugriff (PDF)

Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?

Current treatment options in oncology, 2024-05, Vol.25 (5), p.659-678

2024

Volltextzugriff (PDF)

TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis

American journal of hematology, 2022-08, Vol.97 (8), p.1005-1012

2022

Volltextzugriff (PDF)

Positron emission tomography derived metrics in relapsed or refractory large B‐cell lymphoma with residual disease before autologous stem cell transplant

British journal of haematology, 2023-01, Vol.200 (1), p.35-44

2023

Volltextzugriff (PDF)

Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia

British journal of haematology, 2021-07, Vol.194 (1), p.61-68

2021

Volltextzugriff (PDF)

Why R-CHOP + X is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphoma

Leukemia & lymphoma, 2021-06, Vol.62 (6), p.1302-1312

2021

Volltextzugriff (PDF)

Measurable Residual Disease Monitoring in Lymphoma

Current hematologic malignancy reports, 2023-12, Vol.18 (6), p.292-304

2023

Volltextzugriff (PDF)

A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma

Leukemia & lymphoma, 2022-01, Vol.63 (1), p.74-83

2022

Volltextzugriff (PDF)

Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia

Leukemia research, 2020-11, Vol.98, p.106445-106445, Article 106445

2020

Volltextzugriff (PDF)

Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib

Blood advances, 2020-09, Vol.4 (18), p.4508-4511

2020

Volltextzugriff (PDF)

First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?

Hematology/oncology clinics of North America, 2021-08, Vol.35 (4), p.725-738

2021

Volltextzugriff (PDF)

Interim PET/CT Result Is Not Predictive of Survival in Patients With MYC-rearranged Non–Burkitt Aggressive B-cell Lymphoma

Clinical lymphoma, myeloma and leukemia, 2018-10, Vol.18 (10), p.673-678

2018

Volltextzugriff (PDF)

Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy

Leukemia, 2022-11, Vol.36 (11), p.2669-2677

2022

Volltextzugriff (PDF)

First-Line Therapy for Chronic Lymphocytic Leukemia

Hematology/oncology clinics of North America, 2021-08, Vol.35 (4), p.725-738

2021

Volltextzugriff (PDF)

Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy

Blood, 2022-11, Vol.140 (Supplement 1), p.8609-8610

2022

Volltextzugriff (PDF)

Retrospective Single-Institution Analysis of Patients with Chronic Lymphocytic Leukemia with TP53 alterations Treated First-Line with Bruton's Tyrosine Kinase Inhibitor-Based Therapy

Blood, 2021-11, Vol.138 (Supplement 1), p.394-394

2021

Volltextzugriff (PDF)

POSTER: ABCL-600 Diagnostic Utility of the 18F-FDG PET/CT Scan in EBV-Positive Solid Organ Transplant Patients at Risk for Post-Transplant Lymphoproliferative Disorder

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S203-S203

2023

Volltextzugriff (PDF)

ABCL-600 Diagnostic Utility of the 18F-FDG PET/CT Scan in EBV-Positive Solid Organ Transplant Patients at Risk for Post-Transplant Lymphoproliferative Disorder

Clinical lymphoma, myeloma and leukemia, 2023-09, Vol.23, p.S442-S442

2023

Volltextzugriff (PDF)

Long-term outcomes and circulating tumor DNA analysis from a phase I/II study of lenalidomide and obinutuzumab with CHOP for newly diagnosed diffuse large B-cell lymphoma

Journal of clinical oncology, 2022-06, Vol.40 (16_suppl), p.7553-7553

2022

Volltextzugriff (PDF)

Examination of Clinical and Molecular Characteristics and Treatment Patterns of Adolescent and Young Adult (AYA) Patients with Chronic Lymphocytic Leukemia

Blood, 2020-11, Vol.136 (Supplement 1), p.5-6

2020

Volltextzugriff (PDF)

TP53-altered CLL Treated with Firstline Bruton’s Tyrosine Kinase Inhibitor-based Therapy: A Retrospective Analysis

American journal of hematology, 2022-05, Vol.97 (8), p.1005-1012

2022

Volltextzugriff (PDF)

A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA from Patients Receiving CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma

Blood, 2021-11, Vol.138 (Supplement 1), p.38-38

2021

Volltextzugriff (PDF)

Persistent Overall Response on Early PET/CT Scans during Salvage Therapy for Relapsed or Refractory DLBCL Predicts for Disease Specific Survival

Blood, 2020-11, Vol.136 (Supplement 1), p.7-8

2020

Volltextzugriff (PDF)

Interim PET-CT Result Is Not Predictive of Survival in Patients with MYC-Rearranged Non-Burkitt Aggressive B Cell Lymphoma

Blood, 2017-12, Vol.130, p.4136-4136

2017

Volltextzugriff (PDF)

Menü

Weitere Dienste

Einstellungen

Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic Controls

Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?

TP53‐altered chronic lymphocytic leukemia treated with firstline Bruton's tyrosine kinase inhibitor‐based therapy: A retrospective analysis

Positron emission tomography derived metrics in relapsed or refractory large B‐cell lymphoma with residual disease before autologous stem cell transplant

Clinical and molecular characteristics and treatment patterns of adolescent and young adult patients with chronic lymphocytic leukaemia

Why R-CHOP + X is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphoma

Measurable Residual Disease Monitoring in Lymphoma

Risk assessment with low-pass whole-genome sequencing of cell-free DNA before CD19 CAR T-cell therapy for large B-cell lymphoma

A prospective study on early PET/CT scans during the first cycle of salvage chemotherapy for relapsed or refractory diffuse large B-cell lymphoma

Metastatic lung adenocarcinoma mimicking Richter transformation in a patient with chronic lymphocytic leukemia

Incidental Richter transformation in chronic lymphocytic leukemia patients during temporary interruption of ibrutinib

First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?

Interim PET/CT Result Is Not Predictive of Survival in Patients With MYC-rearranged Non–Burkitt Aggressive B-cell Lymphoma

Impact of conditioning chemotherapy on lymphocyte kinetics and outcomes in LBCL patients treated with CAR T-cell therapy

First-Line Therapy for Chronic Lymphocytic Leukemia

Clonal Hematopoiesis Driven By Recurrent Somatic Mutations but Not with Recurrent Copy Number Alterations Is Associated with Inferior Outcomes in DLBCL after Induction Chemotherapy, but Not CAR19 Therapy

Retrospective Single-Institution Analysis of Patients with Chronic Lymphocytic Leukemia with TP53 alterations Treated First-Line with Bruton's Tyrosine Kinase Inhibitor-Based Therapy

POSTER: ABCL-600 Diagnostic Utility of the 18F-FDG PET/CT Scan in EBV-Positive Solid Organ Transplant Patients at Risk for Post-Transplant Lymphoproliferative Disorder

ABCL-600 Diagnostic Utility of the 18F-FDG PET/CT Scan in EBV-Positive Solid Organ Transplant Patients at Risk for Post-Transplant Lymphoproliferative Disorder

Long-term outcomes and circulating tumor DNA analysis from a phase I/II study of lenalidomide and obinutuzumab with CHOP for newly diagnosed diffuse large B-cell lymphoma

Examination of Clinical and Molecular Characteristics and Treatment Patterns of Adolescent and Young Adult (AYA) Patients with Chronic Lymphocytic Leukemia

TP53-altered CLL Treated with Firstline Bruton’s Tyrosine Kinase Inhibitor-based Therapy: A Retrospective Analysis

A Risk Score Incorporating Low Pass Whole Genome Sequencing of Cell Free DNA from Patients Receiving CD19 CAR T-Cell Therapy for Large B-Cell Lymphoma

Persistent Overall Response on Early PET/CT Scans during Salvage Therapy for Relapsed or Refractory DLBCL Predicts for Disease Specific Survival

Interim PET-CT Result Is Not Predictive of Survival in Patients with MYC-Rearranged Non-Burkitt Aggressive B Cell Lymphoma

Suchergebnisse filtern